Inhibrx Founder and CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors?
Lappe's purchase through family trusts boosts his beneficial ownership to 950,000 shares, or 6% of outstanding equity, as Inhibrx trades near $114 following a 293% gain over the past year.